Corporate Overview

Heron Therapeutics, Inc. (NASDAQ: HRTX) is a biotechnology company developing products using its proprietary Biochronomer® polymer-based drug delivery platform. This drug delivery platform is designed to improve the therapeutic profile of injectable pharmaceuticals by extending their duration of action. The Company's lead product, SUSTOL® (formerly APF530), is being developed for the prevention of both acute- and delayed-onset chemotherapy-induced nausea and vomiting. Heron Therapeutics received a Complete Response Letter to its SUSTOL New Drug Application (NDA) and is targeting a resubmission of the NDA to the U.S. Food and Drug Administration in the fourth quarter of 2014.

More>>

Stock Quote
HRTX (Common Stock)
ExchangeNASDAQ CM (US Dollar)
Price$8.82
Change (%) Stock is Down 0.01 (0.11%)
Volume154,366
Data as of 10/31/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Calendar of Events
November 2014?
Calendar Help
This calendar contains six months of past and future company related information, which may include press releases, SEC filings, calendar events and more. Dates containing information are indicated by a colored background. You may hover your mouse over a date that contains an event to reveal the event or events taking place on that day including a link to additional information. This calendar requires JavaScript to be installed and activated on your browser.
Calendar Icon Legend:
Analyst Meeting
Conference
Conference Presentation
Corporate Conference Call
Custom Events
Earnings Conference Call
Earnings Release
Financial Reports
Mergers & Acquisition Announcement
Guidance Announcement
Other Corporate
Sales Call/Presentation
Sales Release
Shareholders Meeting
News Release
SEC Filings
Presentations
52 Week High
Today
SunMonTueWedThuFriSat
-6-5-4-3-2-11
2345678
9101112131415
16171819202122
23242526272829
30515253545556
Recent NewsMore >>
DateTitle 
08/25/14Heron Therapeutics Appoints Esmé C. Smith as Vice President, General Counsel and Secretary
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 25, 2014-- Heron Therapeutics, Inc. (NASDAQ:HRTX), a specialty pharmaceutical company, today announced that Esmé C. Smith will join the Company as Vice President, General Counsel and Secretary, effective today. Ms. Smith will report to Barry D. Quart, Pharm.D., Heron’s Chief Executive Officer. “Esme brings to her role at Heron over fifteen years of relevant legal and industry experience that will... 
Printer Friendly Version
08/04/14Heron Therapeutics Announces Second Quarter and Year-to-Date 2014 Financial Results
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Aug. 4, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today reported second quarter and year-to-date 2014 financial results and highlighted recent corporate progress. Recent Corporate Highlights On June 30, 2014, Heron announced the closing of an underwritten public offering of 4.8 million shares of common stock at a public offering price of ... 
Printer Friendly Version
06/30/14Heron Therapeutics, Inc. Closes Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 30, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced closing of its underwritten public offering of 4,751,358 shares of common stock at a public offering price of $11.75 per share. As a component of the offering, in lieu of common stock, Heron Therapeutics, Inc. also offered and sold to certain existing large investors pre-funded warrants to purchase up to an a... 
Printer Friendly Version
06/25/14Heron Therapeutics, Inc. Announces Pricing of Underwritten Offering of Common Stock
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Jun. 25, 2014-- Heron Therapeutics, Inc. (NASDAQ: HRTX), a specialty pharmaceutical company, today announced the pricing of an underwritten offering of 4,500,000 shares of its common stock, offered at a price of $11.75 per share. Heron Therapeutics, Inc. has granted the underwriters a 30-day option to purchase up to an additional 675,000 shares of common stock. As a component of the offering, in lieu of co... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Quotes delayed at least 15 minutes. Market data provided by Interactive Data.

Terms & Conditions. Powered and implemented by Interactive Data Managed Solutions.